RSNA 2016: SyntheticMR launches REMyDI for easy quantification of myelin volume in the brain

SyntheticMR AB introduces REMyDI, automatic quantification of myelin volume in the brain. Easy quantification of myelin allows clinicians to follow myelination in the developing brain and monitor myelin degeneration in patients with demyelinating and neurodegenerative disorders. REMyDI is a unique feature of the SyMRI^® post-processing software from SyntheticMR.

Measuring myelin volume with conventional MRI is challenging. With the REMyDI feature in SyMRI, clinicians can now get an automatic volume measurement of myelin from a single 5-6 minute quantitative MRI scan. The automatic post-processing is completed in less than 10 seconds.

The advantage of retrieving a myelin estimation from a quantitative MR sequence that can also provide relaxometry-based volumetry and multiple contrasts is that a large amount of information is collected using a single, 6-minute long acquisition. At Karolinska we have used REMyDI in studies of MS-patients and patients with neurodegenerative diseases”

Tobias Granberg, MD, PhD, Karolinska University Hospital, Sweden.

SyntheticMR introduces REMyDI as a part of SyMRI at the annual RSNA conference in Chicago, November 27 – December 2, 2016. The REMyDI feature is available in the SyMRI Research Edition package and will be available for clinical use in the SyMRI NEURO package in 2017.

SyMRI is compatible with MR scanners from leading vendors and will be demonstrated in the booths of our partners at RSNA. SyMRI is a CE-marked product and is FDA 510(k) pending.